Remdesivir

Independent reference data for Remdesivir (CAS 1809249-37-3), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Documented uses on record

Remdesivir is indicated for the treatment of adult and pediatric patients 28 days of age and older and weighing at least 3 kg for coronavirus disease 2019 (COVID-19) infection requiring hospitalization. It is also indicated for the treatment of non-hospitalized patients with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, including hospitalization or death. Remdesivir was originally granted FDA Emergency Use Authorization (EUA) on May 1, 2020, for use in adults and children withRemdesivir is an antiviral nucleotide analogue used for therapy of severe novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS) coronavirus 2 (CoV-2) infection. Remdesivir therapy is given intravenously for 3 to 10 days and is frequently accompanied by transient, reversible mild-to-moderate elevations in serum aminotransferase levels but has been only rarely linked to instances of clinically apparent liver injury, its hepatic effects being overshadowed by the systemic effects

Synonyms and trade names

Remdesivir; 1809249-37-3; Veklury; GS-5734; 3QKI37EEHE; remdesivirum; GS 5734; GS5734; Remdesivir [USAN]; CHEBI:145994; DTXSID701022537; RefChem:6679; 13C3 GS-5734; 13C3-GS-5734; GS-465124; GS-829143

GHS hazard classification

Reported hazard statements	H302 (33.3%), H315 (33.3%), H319 (33.3%), H335 (33.3%), H372 (33.3%), H373 (66.7%)

H302 (33.3%): Harmful if swallowed [Warning Acute toxicity, oral]

H315 (33.3%): Causes skin irritation [Warning Skin corrosion/irritation]

What the public record says

Remdesivir · CAS 1809249-37-3 · C27H35N6O8P. UNII 3QKI37EEHE.

Source: PubChem / Wikidata; the batch COA governs where values differ.